AR101225A1 - Vacunas de meningococos - Google Patents

Vacunas de meningococos

Info

Publication number
AR101225A1
AR101225A1 ARP150102269A ARP150102269A AR101225A1 AR 101225 A1 AR101225 A1 AR 101225A1 AR P150102269 A ARP150102269 A AR P150102269A AR P150102269 A ARP150102269 A AR P150102269A AR 101225 A1 AR101225 A1 AR 101225A1
Authority
AR
Argentina
Prior art keywords
meningocock
vaccines
polypeptide
meningococcal
composition
Prior art date
Application number
ARP150102269A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR101225A1 publication Critical patent/AR101225A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/116Polyvalent bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
ARP150102269A 2014-07-17 2015-07-16 Vacunas de meningococos AR101225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14177563 2014-07-17

Publications (1)

Publication Number Publication Date
AR101225A1 true AR101225A1 (es) 2016-11-30

Family

ID=51178811

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150102269A AR101225A1 (es) 2014-07-17 2015-07-16 Vacunas de meningococos
ARP230102768A AR130778A2 (es) 2014-07-17 2023-10-17 Vacunas de meningococos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP230102768A AR130778A2 (es) 2014-07-17 2023-10-17 Vacunas de meningococos

Country Status (15)

Country Link
US (2) US11707513B2 (enExample)
EP (1) EP3169358A1 (enExample)
JP (2) JP6687597B2 (enExample)
KR (2) KR20230012100A (enExample)
CN (2) CN106659776A (enExample)
AR (2) AR101225A1 (enExample)
AU (2) AU2015289193A1 (enExample)
BE (1) BE1022878B1 (enExample)
BR (1) BR112017000519A2 (enExample)
CA (1) CA2954729C (enExample)
EA (1) EA038940B1 (enExample)
IL (1) IL249823B (enExample)
MX (1) MX2017000775A (enExample)
SG (2) SG11201610946YA (enExample)
WO (1) WO2016008961A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
CN106795208A (zh) 2014-07-17 2017-05-31 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
JP6687597B2 (ja) 2014-07-17 2020-04-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌ワクチン
US10975131B2 (en) * 2015-10-27 2021-04-13 University Of Massachusetts Factor H-Fc immunotheraphy
CN107151270B (zh) * 2017-03-22 2018-07-31 武汉博沃生物科技有限公司 重组ΔfHbp-NadA融合蛋白载体及其制备方法和应用
CN108939061A (zh) * 2018-08-03 2018-12-07 北京智飞绿竹生物制药有限公司 一种多组分b群脑膜炎球菌疫苗及其制备方法
EP3607967A1 (en) * 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
US11014736B2 (en) 2019-04-18 2021-05-25 Altria Client Services Llc Sliding packs with flip top hinged lids
CN110804101A (zh) * 2019-11-08 2020-02-18 苏州微超生物科技有限公司 B群脑膜炎球菌相关融合蛋白、疫苗及其制备方法与应用
EP4065595A4 (en) * 2019-11-25 2023-12-20 Griffith University IMMUNOGENIC PROTEIN AGAINST GONOCOCCAL INFECTION
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
WO2025077785A1 (zh) * 2023-10-10 2025-04-17 康希诺生物股份公司 一种抗脑膜炎球菌的免疫组合物及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
RU2279889C2 (ru) * 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
BR112012010531A2 (pt) 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
BR112012022669A2 (pt) 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina.
BR112012024348B1 (pt) 2010-03-30 2022-11-08 Children's Hospital & Research Center At Oakland Composição imunogênica, seu uso, proteína de ligação ao fator h de ocorrência não natural, e célula bacteriana geneticamente modificada
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
RU2644340C2 (ru) * 2012-06-14 2018-02-08 Новартис Аг Вакцины для менингококка серогруппы х
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
EP2916512B1 (en) 2014-03-07 2016-08-24 Mitsubishi Electric R&D Centre Europe B.V. Method for classifying a TCP connection carrying HTTP traffic as a trusted or an untrusted TCP connection
JP6687597B2 (ja) 2014-07-17 2020-04-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 髄膜炎菌ワクチン
CN106795208A (zh) 2014-07-17 2017-05-31 葛兰素史密丝克莱恩生物有限公司 修饰的脑膜炎球菌fHbp多肽
KR102722623B1 (ko) 2018-06-21 2024-10-30 바스프 에스이 안정화제로서의 3-페닐-벤조푸란-2-온 디포스페이트 유도체

Also Published As

Publication number Publication date
EA201692554A1 (ru) 2017-07-31
SG10201900041VA (en) 2019-02-27
KR102626831B1 (ko) 2024-01-22
CN106659776A (zh) 2017-05-10
BR112017000519A2 (pt) 2017-11-21
EA038940B1 (ru) 2021-11-12
KR20170029615A (ko) 2017-03-15
US11707513B2 (en) 2023-07-25
AU2019201131A1 (en) 2019-03-07
BE1022878A1 (fr) 2016-09-30
CA2954729C (en) 2023-08-22
CA2954729A1 (en) 2016-01-21
EP3169358A1 (en) 2017-05-24
US12485164B2 (en) 2025-12-02
AU2015289193A1 (en) 2017-02-02
AU2019201131C1 (en) 2021-03-18
AR130778A2 (es) 2025-01-15
CN113827712A (zh) 2021-12-24
SG11201610946YA (en) 2017-01-27
IL249823B (en) 2022-07-01
JP7074793B2 (ja) 2022-05-24
JP2020117523A (ja) 2020-08-06
AU2019201131B2 (en) 2020-08-27
IL249823A0 (en) 2017-03-30
BE1022878B1 (fr) 2016-09-30
US20230414736A1 (en) 2023-12-28
WO2016008961A1 (en) 2016-01-21
MX2017000775A (es) 2017-05-04
US20180214531A1 (en) 2018-08-02
JP2017522319A (ja) 2017-08-10
JP6687597B2 (ja) 2020-04-22
KR20230012100A (ko) 2023-01-25

Similar Documents

Publication Publication Date Title
AR130778A2 (es) Vacunas de meningococos
ES2659418T3 (es) Una estructura de transferencia, un sistema de transferencia y un método para la transferencia de GNL y/o energía eléctrica
CL2016002679A1 (es) Métodos para mejorar o acelerar la recuperación física después la cirugía por fractura de cadera.
CY1123622T1 (el) Τροποποιημενα μηνιγγιτιδοκοκκικα fhbp πολυπεπτιδια
PL3142858T3 (pl) Przepuszczająca powietrze i mikroporowata cienka termoplastyczna membrana
EP3145689A4 (en) Layerless bioprinting via dynamic optical projection and uses thereof
EP3119424A4 (en) Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof
BR112017007466A2 (pt) métodos para preparar uma composição seca e reconstituir uma composição seca, pasta, composição seca, recipiente, kit homeostático, e, seringa.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
MY193650A (en) Extracellular matrix compositions
EP3153794A4 (en) Cooling device, light source device provided with cooling device, and projection-type image display device provided with light source device
CL2016002223A1 (es) Microorganismo recombinante que expresa análogos de avermectina y uso de los mismos.
ZA201805159B (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
PE20161197A1 (es) Sistemas y metodos para reparar membranas y mejorar el rendimiento de los sistemas de membranas impulsados osmoticamente
HUE065328T2 (hu) EXPEC glikokonjugátum vakcinakészítmények
CL2016001746A1 (es) Derivados de hidroxi formamida y sus usos
MX2020004133A (es) Oligosacaridos inmunomoduladores.
MX2017000076A (es) Macromoleculas estrellas compatibles con tensoactivos.
MX2017007577A (es) Compuestos de dihidropirimidin-2-ona y su uso medico.
UY35545A (es) Composiciones y procedimientos para inducir tolerancia inmunitaria a las proteínas factores de coag ulación
CL2018000513A1 (es) Vacunas de pestivirus para temblores congénitos
BR112016022787A2 (pt) método para induzir uma resposta imune em um indivíduo humano, composição imunogênica, e, uso de uma segunda composição imunogênica
BR112015023788A2 (pt) método e sistema para operar dispositivo de recebimento de usuários com perfis de usuário
EP3187249A4 (en) Hollow fiber membrane and hollow fiber membrane module

Legal Events

Date Code Title Description
FC Refusal